Revenue, 2025

USD 1.36 Billion

Forecast, 2035

USD 3.29 Billion

CAGR, 2026-2035

9.24%

Report Coverage

Global

Gene Therapy Clinical Trials Market Trends for 2026

The gene therapy clinical trials market size was valued at US$ 1.36 billion in 2025 and is projected to grow to 1.49 billion in 2026. Forecasts suggest it will reach approximately US$ 3.29 billion by 2035, registering a CAGR of 9.24% during the period.

The gene therapy clinical trials market is primarily driven by the increasing need for personalized medicines and growing research and development activities. The rising prevalence of genetic and rare disorders potentiates the demand for gene therapy. Government organizations support the development of gene therapy through several initiatives and funding. Prominent players collaborate to access advanced technologies and develop innovative products. Artificial intelligence (AI) streamlines the entire clinical trial process and aids in data analysis. The future is promising, with the advancements in genomic technologies.

Key Takeaways

• Gene therapy clinical trials market to crossed USD 1.49 billion by 2026.
• Market projected at USD 3.29 billion by 2035.
• CAGR of 9.24% expected in between 2026 to 2035.
• North America held a major revenue share of approximately 46% in the market in 2025.
• Asia-Pacific is expected to host the fastest-growing market with the fastest CAGR in the coming years.
• By therapy modality, the in vivo gene therapy segment dominated the gene therapy clinical trials market with a share of approximately 55% in 2025.
• By therapy modality, the ex vivo gene therapy segment is expected to expand rapidly in the market in the coming years.
• By vector/delivery platform, the AAV (adeno-associated virus) segment led the market with a share of approximately 45% in 2025.
• By vector/delivery platform, the genome editing segment is expected to witness the fastest growth in the market over the forecast period.
• By therapeutic area, the oncology segment accounted for the highest revenue share of approximately 35% in the market in 2025.
• By therapeutic area, the neurology/CNS segment is expected to show the fastest growth in the gene therapy clinical trials market over the forecast period.
• By clinical phase, the phase I/ I/II segment held a dominant revenue share of approximately 60% in the market in 2025.
• By clinical phase, the Phase III & pivotal/confirmatory segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By route of administration, the intravenous/systemic segment contributed the biggest revenue share of approximately 40% in the market in 2025.
• By route of administration, the intrathecal/intracerebroventricular segment is expected to grow with the highest CAGR in the market during the studied years.

What Comes Under Gene Therapy Clinical Trials Market?

The gene therapy clinical trials market covers sponsored studies that evaluate in vivo and ex vivo gene delivery to treat or prevent disease using viral vectors (AAV, lentivirus, adenovirus, HSV), non-viral platforms (plasmid DNA, lipid nanoparticles), genome editing (CRISPR/Cas, ZFN, TALEN), and cell-based gene therapies (e.g., CAR-T, engineered T/NK, HSC). It spans trial planning, site activation, vector and cell handling logistics, manufacturing for clinical supply, and data/biomarker operations. Growth is driven by expanding pipelines, maturing regulatory pathways, better vector engineering and manufacturing capacity, and strong investment in rare diseases, oncology, and ophthalmology.

Gene Therapy Clinical Trials Market Trends

Increasing Collaboration: Major players collaborate to access advanced technologies and expand their geographical presence. Companies use each other’s expertise to develop innovative products and accelerate time-to-market approval.

• In April 2025, BRIC-inStem, in collaboration with CMC Vellore and other medical institutions and hospitals, conducted the first gene therapy trials for hemophilia. This collaboration underscores the strategic importance of biotechnology in shaping India’s future economy and public health infrastructure.
• In February 2025, Biogen, Inc. announced a collaboration with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a first-in-class disease-modifying medicine for the treatment of Dravet syndrome. The global Phase 3 registrational study is expected to initiate in the second quarter of 2025, with a pivotal data readout anticipated in the second half of 2027.

What are the Different Market Trends?

• Technological Advancements: Advances in gene editing tools like CRISPR and improved viral vectors are enhancing precision, safety, and delivery efficiency in gene therapy trials. These innovations reduce off-target effects and support better clinical outcomes.
• Oncology Therapeutic Focus: Cancer remains a primary focus due to the success of CAR-T and other engineered cell therapies. Many trials target hematological cancers such as leukemia and lymphoma, with increasing research on solid tumors.
• Strong Regulatory Frameworks: Regulatory agencies implement strict guidelines to ensure safety, long-term monitoring, and ethical standards, enabling faster approvals for therapies addressing serious and rare diseases.
• Rising Investments: Growing funding from biotechnology companies, pharmaceutical firms, and venture capital is accelerating clinical research and expanding gene therapy pipelines worldwide.
• Expansion in Rare Disease Research: Gene therapy trials increasingly target rare genetic disorders, offering potential curative treatments.

How Can AI Improve the Gene Therapy Clinical Trials Market?

AI and machine learning (ML) algorithms can transform the complex clinical trial process by assisting in patient selection, real-time monitoring, and toxicity prediction. AI introduces automation in clinical trials, saving time and costs for healthcare professionals and sponsors. AI and ML can analyze vast amounts of data and predict potential outcomes of a particular gene therapy. They can help researchers in screening large numbers of candidates rapidly and select designs that fulfill the desired criteria, similar to their use in target identification. AI and ML enhance the efficiency and accuracy of clinical trials.

Market Dynamics

Driver

Demand for Gene Therapy

The major growth factor for the gene therapy clinical trials market is the growing demand for gene therapy. Gene therapy is widely preferred as it directly cures a disease from its root cause. The rising prevalence of cancer, neurological, genetic, and rare disorders increases the need for gene therapy. Unlike small molecules, gene therapy provides targeted treatment, which is beneficial to patients, resulting in fewer side effects. Regulatory agencies necessitate the conduct of clinical trials to assess a product’s safety and efficacy before market approval. As of 15th August 2025, the U.S. Food and Drug Administration has approved 46 cell and gene therapy products. 

Restraint

Lack of Access

The advanced gene therapy in clinical trials is generally inaccessible to people from rural areas. Rural areas lack skilled professionals with experience in executing gene therapy clinical trials and access to tools that can pre-emptively assess the risk to patients based on data.

Opportunity

What is the Future of the Gene Therapy Clinical Trials Market?

The market future is promising, driven by the advancements in genomic technologies. Innovative genomic techniques, such as CRISPR-Cas9, are widely adopted to revolutionize gene therapy development. The CRISPR-Cas9 technique offers specific modifications of target genes, resulting in high accuracy and efficiency. Prime editing and approaches involving CRISPR-Cas effectors present future opportunities for researchers as they are more versatile and efficient tools for manipulating genetic material. This technique offers unprecedented precision in genome editing. It guides Cas9 to the target DNA and provides the necessary template for the insertion, deletion, or conversion of specific DNA sequences.

Key Indicators and Highlights

Segmental Insights

By Therapy Modality

Explanation

• In vivo Gene Therapy delivers genetic material directly into the patient’s body and holds 55% and dominates due to simpler administration and expanding clinical applications.
• Ex vivo Gene-modified Cell Therapy involves modifying cells outside the body before reinfusion and holds 45% but does not dominate due to higher complexity and multi-step processing requirements.

Which Therapy Modality Segment Dominated the Gene Therapy Clinical Trials Market?

By therapy modality, the in vivo gene therapy segment held a dominant presence in the market by 55% in 2025. This is due to the high simplicity and efficiency of the in vivo process. The in vivo refers to the direct delivery of genetic material into the patient’s body through the parenteral route. The genetic material is transferred using a vector, aiding in its targeted delivery. Advancements in vector technology and cost-effectiveness potentiate the demand for in vivo gene therapy.

By therapy modality, the ex vivo gene therapy segment is expected to grow at the fastest CAGR in the market during the forecast period. Ex vivo gene therapy involves removing specific cells from a person, genetically altering them in a laboratory, and transplanting them back into the person. This technique enables researchers to develop gene therapy against a wide range of disorders as they can modify the genetic material based on a patient’s needs.

By Vector/Delivery Platform

Explanation

• AAV (Adeno-Associated Virus) vectors lead gene delivery due to safety and tissue targeting and hold 45% and dominate because of strong clinical validation and broad therapeutic use.
• Lentiviral Vectors enable stable gene integration and hold 25% but do not dominate due to higher safety monitoring requirements.
• Adenoviral/Oncolytic & Others support high-efficiency gene transfer and hold 15% but do not dominate due to immunogenicity concerns and limited persistence.
• Non-viral (plasmid DNA, LNP/mRNA) platforms offer flexible delivery and hold 10% but do not dominate as they are still evolving for long-term therapeutic applications.
• Genome Editing (CRISPR, ZFN, TALEN) enables precise gene modification and holds 5% but does not dominate due to early-stage clinical adoption and regulatory complexity.

How the AAV (Adeno-Associated Virus) Segment Dominated the Gene Therapy Clinical Trials Market?

By vector/delivery platform, the AAV (adeno-associated virus) segment held the largest revenue share of the market by 45% in 2025. This segment dominated because AAV vectors are non-pathogenic and can be engineered to carry specific genes into target cells. These vectors do not cause any harm or illness to humans. They can directly target the cause of a disease and change the way a cell functions. AAV vectors are highly preferred as they are non-integrating, i.e., they do not insert their DNA into the cell’s genome. They can persist within a patient’s body even for a lifetime.

By vector/delivery platform, the genome editing segment is expected to grow with the highest CAGR in the market during the studied years. Certain genome editing techniques, such as CRISPR, ZFN, TALEN, and AAV/LNP, facilitate gene delivery within patients. These techniques enable researchers to knock out faulty genes and insert correct genes. They provide targeted treatment to recognize specific DNA sequences. CRISPR-based genome-scale screening methods can overcome numerous technical hurdles associated with other contemporary screening technologies.

By Therapeutic Area

Explanation

• Oncology accounts for 35% and dominates due to high disease burden and strong demand for advanced gene-based therapies.
• Rare/Genetic & Metabolic Disorders contribute 19% and address inherited conditions with growing precision medicine adoption.
• Ophthalmology (retinal) holds 15% and serves a focused but expanding gene therapy application area.
• Hematology (hemoglobinopathies, coagulation) represents 10% and supports targeted treatment of blood disorders.
• Neurology/CNS accounts for 4% and remains limited due to delivery challenges across the blood-brain barrier.
• Cardiovascular Diseases hold 10% and support emerging regenerative and gene-based cardiac therapies.
• Infectious Diseases contribute 4% and focus on developing novel antiviral gene approaches.
• Others account for 3% and include niche or early-stage therapeutic areas with limited adoption.

Why Did the Oncology Segment Dominate the Gene Therapy Clinical Trials Market?

By therapeutic area, the oncology segment contributed the biggest revenue share of the market by 35% in 2025. This is due to the rising prevalence of cancer and the need for personalized treatment. Many tumors are caused by genetic mutations, which lead to abnormal cell growth. Gene therapy alters the genetic material of a patient that causes cancer, ultimately curing the cancer from its root cause. As of August 2025, 1,472 studies are registered related to gene therapy in cancer on the clinicaltrials.gov website.

By therapeutic area, the neurology/CNS segment is expected to expand rapidly in the market in the coming years. Ongoing efforts are made to develop gene therapy for expanding applications, such as neurological disorders. Government organizations encourage the general public to screen for and aid in the early diagnosis of neurological disorders. This creates a new wave for the therapeutic development of gene-targeted therapies, offering hope for modifying the natural course of the disease.

By Clinical Phase

Explanation

• Phase I/I/II studies account for 60% and dominate due to heavy focus on early safety, dosing, and proof-of-concept in gene therapy development.
• Phase II trials contribute 20% and evaluate efficacy and optimal dosing in targeted patient populations.
• Phase III & Pivotal/Confirmatory studies represent 15% and validate safety and efficacy for regulatory approval.
• Post-marketing/Long-term Follow-up (LTFU) holds 5% and tracks long-term safety and durability after commercialization.

Which Clinical Phase Segment Led the Gene Therapy Clinical Trials Market?

By clinical phase, the phase I/ I/II segment led the global market by 60% in 2025. This is due to the need to establish a new drug’s safety and dose range. Phase I clinical trials are conducted at a small scale, usually involving 20-100 healthy volunteers. If a treatment is found safe in a phase I clinical trial, a phase 2 clinical trial is conducted on a larger patient population. Phase II trials help to determine the effectiveness of a therapeutic.

By clinical phase, the Phase III & pivotal/confirmatory segment is expected to witness the fastest growth in the market over the forecast period. Phase III trials are conducted on a much larger scale, involving hundreds to thousands of patients, to assess a drug’s efficacy. Only 25-30% of drugs reach Phase III trials. The results of a Phase III trial are essential as regulatory agencies approve a product based on the efficacy and safety required to be approved and commercialized.

By Route of Administration

Explanation

• Intravenous/Systemic delivery accounts for 40% and dominates due to broad distribution capability and established clinical use for gene and cell therapies.
• Intravitreal/Subretinal delivery contributes 15% and supports targeted retinal treatments in ophthalmic applications.
• Intrathecal/Intracerebroventricular delivery holds 10% and enables direct CNS administration but remains limited due to procedural complexity.
  Intratumoral/Regional delivery represents 10% and focuses on localized treatment of solid tumors.
• Hepatic-targeted, Intramuscular & Others account for 25% and include emerging and specialized delivery approaches across multiple therapeutic areas.

What Made Intravenous/Systemic the Dominant Segment in the Gene Therapy Clinical Trials Market?

By route of administration, the intravenous/systemic segment accounted for the highest revenue share of the market by 40% in 2025. Gene therapy is commonly administered through the intravenous route, allowing it to circulate throughout the body and reach the target site. It is widely preferred due to its faster onset of action and high bioavailability. The demand for minimally invasive gene delivery and the need to avoid the complexities of direct injection into multiple tissues make the intravenous route a suitable choice.

By route of administration, the intrathecal/intracerebroventricular segment is expected to show the fastest growth over the forecast period. The intrathecal/intracerebroventricular route is generally used for patients with neurological disorders. This helps healthcare professionals to deliver the gene therapy directly into the CNS. This route provides targeted treatment and reduces systemic side effects.

Regional Analysis

Which Factors Govern the Gene Therapy Clinical Trials Market in North America?

North America dominated the global market in 2025. The presence of key players, the availability of a favorable clinical trial infrastructure, and increasing investments are the major growth factors of the market in North America. The region has an expanding manufacturing capacity, favoring commercial-scale manufacturing of gene therapy. Government organizations launch initiatives to support clinical trials and the development of novel gene therapy products.

U.S. Market Trends

Key players, such as Pfizer, Inc., Biogen, and Regeneron Pharmaceuticals, are the major contributors to the market in the U.S. The American Society of Gene & Cell Therapy (ASGCT) reported that 79 trials were initiated in Q1. About 12 start-ups collectively raised approximately $304.5 million in Q1 seed and Series A funding.

Canada Market Trends

The Canadian Institutes of Health Research (CIHR) provides funding for bringing rare disease gene therapies to clinical readiness as part of the National Strategy for Drugs for Rare Diseases. In 2023, it announced investments of up to $1.5 billion over three years. In August 2024, Ocugen, Inc. announced that Health Canada approved a “No Objection Certificate” to initiate the OCU400 Phase 3 clinical trial in Canada.

Expanding Clinical Trial Infrastructure Promotes the Asia-Pacific

Asia-Pacific is expected to grow at the fastest CAGR in the gene therapy clinical trials market during the forecast period. The rapidly expanding clinical trial infrastructure and affordable services encourage foreign investors to conduct their clinical trials in Asia-Pacific countries, like China, Japan, and India. The increasing number of local sponsors and collaborations among key players fosters market growth. The growing research and development activities and the rising adoption of advanced technologies contribute to market growth.

China Market Trends

As of August 2025, a total of 494 clinical trials were registered in China related to gene therapy. In December 2024, Bayer announced that it had entered into agreements with Epigenic Therapeutics (Shanghai) Biotechnology Co., Ltd., Shanghai Immunocan Biotech Co., Ltd., and AccurEdit Therapeutics Co., Ltd. as resident companies. This will enable the companies to access worldwide resources and expertise, accelerating breakthrough innovations in CGT.

India Market Trends

In India, 24 clinical trials related to gene therapy are registered as of August 2025. Government agencies promote the indigenous development of gene therapy through “Make in India” and “Atmanirbhar Bharat” initiatives. In April 2024, the President of India launched India’s first home-grown gene therapy for cancer at IIT Bombay.

SWOT Analysis

Strengths

• The use of CRISPR/Cas9 and improved viral vectors (AAV, lentiviral) boosts accuracy and effectiveness.
• Significant funding from pharmaceutical companies and venture capitalists is speeding up the development process, resulting in many early-stage trials.

Weaknesses

• Numerous trials are being conducted, lacking established protocols, resulting in uncertain results.
• Challenges related to technical aspects of increasing production and the high expenses associated with manufacturing.

Opportunities

• Focusing more on rare diseases that have high unmet needs offers great growth opportunities.
• Improved delivery systems like lipid nanoparticles and non-viral vectors are increasing effectiveness and safety.

Threats

• Strict and changing regulations lead to delays in approvals and higher expenses.
• Significant risk of trial failures, which can severely impact company stock and destroy investor trust.

Value Chain Analysis of the Gene Therapy Clinical Trials Market

R&D

• Researchers develop novel and innovative gene therapy products using advanced genomic technologies. They also develop novel delivery systems for ensuring targeted delivery.
• Key Players: CRISPR Therapeutics, Intellia Therapeutics, and Allogene Therapeutics

Clinical Trials & Regulatory Approvals

• Gene therapy clinical trials are conducted to assess its safety and efficacy in a large patient population, enabling regulatory agencies to approve a product for market authorization.
• Key Players: Novartis AG, Capsida Biotherapeutics, Inc., and Expression Therapeutics LLC

Patient Support & Services

• Patient support & services in gene therapy clinical trials refer to providing comprehensive assistance to clinical trial participants by addressing several logistical and educational challenges.

Top Companies in the Gene Therapy Clinical Trials Market

• Novartis
• Roche/Genentech
• Pfizer
• Biogen
• Regeneron
• Sarepta Therapeutics
• Bluebird bio
• CRISPR Therapeutics
• Editas Medicine
• Intellia Therapeutics
• Verve Therapeutics
• Sana Biotechnology
• Beam Therapeutics

Top Companies and Their Offerings in the Market

Latest Announcement by Industry Leaders

Michael Culme-Seymour, Regional Vice President for APAC at Cencora, commented that the percentage of clinical trials in the APAC region is tremendously increasing, from 8% in 2013 to 29% in 2023. The company expands and strengthens its capabilities to meet the growing demand for premium specialty logistics services as more companies establish clinical trials. There are more than 650 cell and gene therapy (CGT) clinical trials underway in the region.

Recent Developments in the Gene Therapy Clinical Trials Market

• In August 2025, UMass Chan Medical School conducted a Phase I/II clinical trial of a dual vector gene therapy for GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases. The researchers were able to induce the production of the appropriate enzyme.
• In February 2025, the EMA Committee for Advanced Therapies classified OCU400 as an ATMP, making it the first gene therapy in Phase III for broad retinitis pigmentosa. Ocugen developed the OCU400 and aims to file the Marketing Authorization in 2026.

Segments Covered in the Report

By Therapy Modality

• In vivo Gene Therapy
• Ex vivo Gene-modified Cell Therapy

By Vector/Delivery Platform

• AAV (Adeno-Associated Virus)
• Lentiviral Vectors
• Adenoviral/Oncolytic & Others
• Non-viral (plasmid DNA, LNP/mRNA DNA templates)
• Genome Editing (CRISPR, ZFN, TALEN; incl. AAV/LNP delivered)

By Therapeutic Area

• Oncology
• Rare/Genetic & Metabolic Disorders
• Ophthalmology (retinal)
• Hematology (hemoglobinopathies, coagulation)
• Neurology/CNS
• Cardiovascular Diseases
• Infectious Diseases
• Others

By Clinical Phase

• Phase I/ I/II
• Phase II
• Phase III & Pivotal/Confirmatory
• Post-marketing/Long-term Follow-up (LTFU) cohorts

By Route of Administration

• Intravenous/Systemic
• Intravitreal/Subretinal
• Intrathecal/Intracerebroventricular
• Intratumoral/Regional
• Hepatic-targeted, Intramuscular & Others

By Region 

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait